Related Experiment Video

Updated: Aug 26, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Emerging Therapeutic Targets for Heart Failure

Maneesha Sharma1, Lokesh Kumar Bhatt2

  • 1Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.

Current Cardiology Reports
|October 4, 2022
PubMed

Insights

Heart failure is a growing global epidemic. This review explores novel therapeutic targets, including RUNX1 and MFGE8, offering potential new treatments for heart failure patients.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Heart failure affects over 26 million globally, with increasing prevalence.
  • Current treatment strategies show limited success in improving survival and symptom management.
  • The incidence of chronic heart failure is rising, projected to increase by 46% by 2030.

Purpose of the Study:

  • To review emerging molecular targets for novel heart failure therapies.
  • To highlight potential treatment avenues beyond current management strategies.

Main Methods:

  • Literature review of recent research on heart failure therapeutic targets.
  • Analysis of specific molecular targets and their potential roles in heart failure.

Main Results:

  • Identified several prospective targets: Runx1 transcription factor (RUNX1), MFGE8 protein, neuraminidase 1 (NEU1), GRK5, GPER1, UTR, CD47, and RXFP1.
  • These targets represent diverse pathways implicated in heart failure pathophysiology.

Conclusions:

  • Emerging targets like RUNX1, MFGE8, NEU1, GRK5, GPER1, UTR, CD47, and RXFP1 show promise for new heart failure treatments.
  • Further investigation into these targets may lead to improved therapeutic approaches and patient outcomes.
Abstract

Keywords:
GPER1GRK5Heart failureMFGE8NEU1RUNX1

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.0K
Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K